Page last updated: 2024-09-03

olmesartan medoxomil and Hypertension, Renal

olmesartan medoxomil has been researched along with Hypertension, Renal in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Igata, H; Imanishi, M; Kawaguchi, N; Kuroita, T; Kusumoto, K; Nagaya, H; Nishigaki, N; Ojima, M; Sakamoto, H; Tsuboi, A; Yamaguchi, F1
Akizawa, T; Aoshima, Y; Hirai, Y; Honda, H; Hosaka, N; Michihata, T1
Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H1
Hayashi, K; Honda, M; Kubota, E; Matsuda, H; Okubo, K; Ozawa, Y; Saruta, T; Takamatsu, I; Tatematsu, S; Tokuyama, H; Wakino, S1

Trials

1 trial(s) available for olmesartan medoxomil and Hypertension, Renal

ArticleYear
Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2012, Volume: 34, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; Female; Glycation End Products, Advanced; Humans; Hypertension, Renal; Imidazoles; Inflammation; Kidney Failure, Chronic; Lysine; Male; Olmesartan Medoxomil; Oxidative Stress; Pilot Projects; Prospective Studies; Renal Dialysis; Telmisartan; Tetrazoles; Treatment Outcome

2012

Other Studies

3 other study(ies) available for olmesartan medoxomil and Hypertension, Renal

ArticleYear
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    European journal of pharmacology, 2011, Nov-01, Volume: 669, Issue:1-3

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Blood Glucose; Blood Pressure; CHO Cells; Cricetinae; Cricetulus; Dogs; Hypertension; Hypertension, Renal; Imidazoles; Insulin; Male; Olmesartan Medoxomil; Oxadiazoles; Protective Agents; Proteinuria; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Tetrazoles

2011
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
    Journal of the American Society of Nephrology : JASN, 2003, Volume: 14, Issue:5

    Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Hydralazine; Hypertension, Renal; Imidazoles; Immunohistochemistry; In Vitro Techniques; Kidney; Lipids; Lysine; Male; Olmesartan Medoxomil; Oxidation-Reduction; Proteinuria; Rats; Tetrazoles

2003
Differential regulation of elevated renal angiotensin II in chronic renal ischemia.
    Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:1

    Topics: Angiotensin I; Angiotensin II; Animals; Chronic Disease; Chymases; Cilazapril; Dogs; Hemodynamics; Hypertension, Renal; Imidazoles; Ischemia; Kidney; Male; Oligopeptides; Olmesartan Medoxomil; Peptidyl-Dipeptidase A; Renal Circulation; Renin-Angiotensin System; Serine Endopeptidases; Tetrazoles

2002